Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MRT-2359 by Monte Rosa Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
MRT-2359 is under clinical development by Monte Rosa Therapeutics and currently in Phase II for Human Epidermal Growth Factor Receptor...
MRT-2359 by Monte Rosa Therapeutics for Bladder Cancer: Likelihood of Approval
MRT-2359 is under clinical development by Monte Rosa Therapeutics and currently in Phase II for Bladder Cancer. According to GlobalData,...
MRT-2359 by Monte Rosa Therapeutics for Prostate Cancer: Likelihood of Approval
MRT-2359 is under clinical development by Monte Rosa Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Monte Rosa Therapeutics's MRT-2359?
MRT-2359 is a small molecule commercialized by Monte Rosa Therapeutics, with a leading Phase II program in Small-Cell Lung Cancer....
MRT-2359 by Monte Rosa Therapeutics for Small-Cell Lung Cancer: Likelihood of Approval
MRT-2359 is under clinical development by Monte Rosa Therapeutics and currently in Phase II for Small-Cell Lung Cancer. According to...